Effects of Caffeine on Women's Sexual Arousal

Not Applicable

Withdrawn

• Conditions: Sexual Behavior
• Interventions: Dietary Supplement: Caffeine; Dietary Supplement: Placebo

• Registration Number: NCT01242046
• Lead Sponsor: University of Texas at Austin

Brief Summary

The key research question in this study is whether or not caffeine facilitates genital sexual arousal in women in the presence of an external erotic stimulus. Caffeine's impact on the human sexual response cycle has yet to be studied in the field, so the goal is to determine if this substance will have any impact on genital arousal well as potentially identify the mechanisms underlying its ability to do so. Considering that this will be a single blind study, a key goal of the project is to determine how participant expectations regarding what they ingest will impact their subjective sexual arousal. At present, we hypothesize that, as caffeine's stimulant properties increase a human's heart rate and blood pressure, caffeine intake will facilitate genital arousal.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-11-15
• Study First Submitted QC: 2010-11-15
• Study First Posted: 2010-11-16
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-26
• Last Update Posted: 2015-05-27

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Women aged 18 or older
• Heterosexual
• Experiencing regular menstrual cycles (not more than 1 missed menstrual period in the past 6 months).
• Currently involved in a stable, sexually active relationship.
• Fluent in the English language.

Exclusion Criteria

• Self-report of sexual aversion or distress; or of distress related to a history of unwanted or coercive sexual contact.
• Perimenopausal or menopausal status, or >1 missed menstrual period in the previous 6 months; or currently pregnant, breastfeeding, or having breastfed within the past 3 months; or clinically significant untreated renal or endocrine disease.
• History of HIV infection or active, untreated pelvic, vaginal, or urinary tract infection including sexually transmitted diseases such as chlamydia, genital herpes, gonorrhea, or syphilis.
• Previous major pelvic surgery that may have caused nerve damage, including hysterectomy, vulvectomy, circumcision, colostomy, cystostomy, or serious bladder, rectal, or abdominal surgery; or neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal cord damage.
• Self-report of an untreated psychosis (e.g., bipolar disorder or schizophrenia).
• Women who do not use caffeine products regularly (i.e., on a daily basis).
• Women receiving any of the following medications will be excluded from the study, as they have been shown to alter sexual function or arousal response: Dehydroepiandrosterone (DHEA), testosterone and other androgens, estrogens (except oral contraceptives), progesterone, tamoxifen, raloxifene, and other selective estrogen receptor modulators (SERMs), Beta blockers or other drugs that affect the autonomic nervous system and/or cardiovascular system, any approved or experimental medications or treatments used to enhance the sexual response (e.g., sildenafil), and antidepressants

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Caffeine	Caffeine	Participants will ingest a tablet with 400 mg caffeine
Placebo	Placebo	Participants will ingest an inert placebo tablet

Primary Outcome Measures

Name	Time	Method
Sexual arousal	15 minutes post administration of drug or placebo	Vaginal pulse amplitude, as measured by a vaginal photoplethysmograph

Trial Locations

Locations (1)

University of Texas at Austin; 🇺🇸 Austin, Texas, United States